

Stephen B Fox

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6055926/stephen-b-fox-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

310
papers

25,192
citations

78
h-index

153
g-index

326
ext. papers

28,795
ext. citations

6.9
avg, IF

6.34
L-index

#	Paper	IF	Citations
310	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 10393-8	11.5	1562
309	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 262-72	9.7	1485
308	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. <i>Clinical Cancer Research</i> , 2008 , 14, 5198-208	12.9	1044
307	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. <i>Nature Medicine</i> , 2009 , 15, 907-13	50.5	1034
306	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , 2012 , 13, 1011-9	21.7	983
305	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5373-80	2.2	841
304	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2654-63	2.2	810
303	Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4142-8	2.2	593
302	Lymphangiogenesis and lymphatic vessel remodelling in cancer. <i>Nature Reviews Cancer</i> , 2014 , 14, 159-73	13	467
301	Breast cancer prognostic classification in the molecular era: the role of histological grade. <i>Breast Cancer Research</i> , 2010 , 12, 207	8.3	459
300	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <i>Modern Pathology</i> , 2011 , 24, 157-67	9.8	447
299	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018 , 24, 986-993	50.5	420
298	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 134-47	4	411
297	Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. <i>Journal of Pathology</i> , 1995 , 177, 275-83	9.4	369
296	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4803-10	2.2	364
295	Thymidine phosphorylase is angiogenic and promotes tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 998-1002	11.5	336
294	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017 , 24, 311-335	5.1	299

293	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in</i>	5.1	293
292	No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. <i>Nature Genetics</i> , 2008 , 40, 650-5	36.3	230
291	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016 , 68, 5-21	7.3	220
290	Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. <i>Clinical Cancer Research</i> , 2009 , 15, 1417-27	12.9	217
289	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. <i>Oncogene</i> , 2011 , 30, 2810-22	9.2	212
288	VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. <i>Cancer Cell</i> , 2012 , 21, 181-95	24.3	208
287	Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. <i>Lancet Oncology, The</i> , 2001 , 2, 278-89	21.7	200
286	Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4562-8	12.9	198
285	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015 , 75, 5228-34	10.1	196
284	Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. <i>Clinical Cancer Research</i> , 2004 , 10, 7965-71	12.9	196
283	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. <i>BMC Medical Genomics</i> , 2014 , 7, 23	3.7	170
282	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	167
281	The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. <i>Journal of Pathology</i> , 2003 , 200, 183-94	9.4	166
280	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology, The</i> , 2017 , 18, 52-62	21.7	164
279	Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. <i>Journal of Pathology</i> , 1995 , 176, 183-90	9.4	162
278	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. <i>BMC Cancer</i> , 2008 , 8, 142	4.8	161
277	First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. <i>British Journal of Cancer</i> , 2006 , 95, 1611-25	8.7	161
276	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2766-71	11.5	156

275	Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3623-8	2.2	156
274	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016 , 29, 1155-64	9.8	154
273	Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival. <i>Breast Cancer Research and Treatment</i> , 1994 , 29, 109-16	4.4	152
272	The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. <i>British Journal of Cancer</i> , 2009 , 100, 405-11	8.7	150
271	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 590-600	4.5	133
270	The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. <i>Breast Cancer Research and Treatment</i> , 1994 , 29, 41-9	4.4	130
269	Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. <i>Journal of Hepatology</i> , 2007 , 47, 316-24	13.4	129
268	The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 7658-63	12.9	128
267	Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. <i>British Journal of Cancer</i> , 2003 , 88, 718-25	8.7	126
266	Prognostic value of angiogenesis in operable non-small cell lung cancer. <i>Journal of Pathology</i> , 1996 , 179, 80-8	9.4	125
265	Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. <i>Breast Cancer Research</i> , 2011 , 13, R47	8.3	124
264	The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. <i>Cancer Research</i> , 2010 , 70, 1573-84	10.1	124
263	Histological quantitation of tumour angiogenesis. <i>Apmis</i> , 2004 , 112, 413-30	3.4	123
262	Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 23-33	3.2	121
261	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. <i>Modern Pathology</i> , 2013 , 26, 1545-53	9.8	119
260	Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. <i>Journal of Pathology</i> , 2004 , 203, 721-8	9.4	119
259	Breast tumour angiogenesis. <i>Breast Cancer Research</i> , 2007 , 9, 216	8.3	117
258	Tumour angiogenesis. <i>Journal of Pathology</i> , 1996 , 179, 232-7	9.4	117

257	Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013 , 37, e1-11	6.7	109
256	Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1044-9	9.7	109
255	Adrenomedullin and tumour angiogenesis. <i>British Journal of Cancer</i> , 2006 , 94, 1-7	8.7	109
254	High resolution melting for mutation scanning of TP53 exons 5-8. <i>BMC Cancer</i> , 2007 , 7, 168	4.8	108
253	Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. <i>Clinical Cancer Research</i> , 2009 , 15, 1046-51	12.9	106
252	The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 137-47	4.4	100
251	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 367-376	8.9	99
250	Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 227-34	2.2	98
249	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Molecular Oncology</i> , 2014 , 8, 656-68	7.9	97
248	A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. <i>Journal of Molecular Diagnostics</i> , 2009 , 11, 543-52	5.1	92
247	Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. <i>Breast Cancer Research and Treatment</i> , 2005 , 93, 237-46	4.4	92
246	Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. <i>Journal of Pathology</i> , 2003 , 201, 573-80	9.4	91
245	Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. <i>British Journal of Cancer</i> , 2009 , 101, 1749-57	8.7	90
244	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016 , 7, 621	8.4	90
243	HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. <i>Breast Cancer Research</i> , 2010 , 12, R46	8.3	87
242	Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. <i>Molecular and Cellular Biology</i> , 2011 , 31, 4609-22	4.8	84
241	Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. <i>Molecular Oncology</i> , 2017 , 11, 208-219	7.9	83
240	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020 , 250, 667-684	9.4	83

239	Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. <i>Cancer Prevention Research</i> , 2011 , 4, 1002-10	3.2	82
238	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. <i>Journal of Pathology</i> , 2002 , 198, 502-10	9.4	82
237	Subtypes of familial breast tumours revealed by expression and copy number profiling. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 661-77	4.4	81
236	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , 2016 , 13, e1002204	11.6	81
235	c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. <i>Cancer Research</i> , 2004 , 64, 6563-70	10.1	80
234	The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. <i>British Journal of Cancer</i> , 2004 , 91, 954-8	8.7	80
233	Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. <i>Clinical Cancer Research</i> , 2004 , 10, 3521-7	12.9	79
232	Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. <i>Journal of Pathology</i> , 2013 , 231, 413-23	9.4	73
231	Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1230-7	4	72
230	BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 467-74	12.9	72
229	Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. <i>Lancet, The</i> , 1995 , 345, 1205-9	4.0	69
228	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , 2017 , 49, 141-155	1.6	68
227	Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. <i>Annals of Oncology</i> , 1999 , 10, 707-13	10.3	68
226	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4569-4577	12.9	65
225	Prognostic Significance of PD-L1 and CD8 Immune Cells in HPV Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 295-304	12.5	65
224	Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. <i>Clinical Cancer Research</i> , 2002 , 8, 1075-81	12.9	65
223	Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. <i>BMC Cancer</i> , 2008 , 8, 59	4.8	63
222	Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. <i>Breast Cancer Research</i> , 2011 , 13, R9	8.3	62

221	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011 , 13, R110	8.3	62
220	Ductal Carcinoma Biology, Biomarkers, and Diagnosis. <i>Frontiers in Oncology</i> , 2017 , 7, 248	5.3	61
219	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. <i>Endocrine-Related Cancer</i> , 2006 , 13, 921-30	5.7	60
218	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019 , 10, 3935	17.4	59
217	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58
216	Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. <i>Investigational New Drugs</i> , 1997 , 15, 15-28	4.3	57
215	Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 611-8	8.9	55
214	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 147-51	4.8	55
213	Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. <i>Oncogene</i> , 2007 , 26, 132-41	9.2	55
212	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
211	Preoperative β -Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1803-1811	12.9	52
210	The genomic landscape of pheochromocytoma. <i>Journal of Pathology</i> , 2015 , 236, 78-89	9.4	51
209	Role of p53 in the progression of gastric cancer. <i>Oncotarget</i> , 2014 , 5, 12016-26	3.3	51
208	BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. <i>British Journal of Cancer</i> , 2009 , 101, 1168-74	8.7	51
207	CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. <i>Cancer Research</i> , 2004 , 64, 6075-81	10.1	51
206	Down-regulation of phosphatidylinositol 3Pkinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2673-80	12.9	49
205	Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. <i>Journal of Pathology</i> , 2004 , 202, 313-20	9.4	48
204	The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. <i>Breast Cancer Research and Treatment</i> , 1995 , 36, 219-26	4.4	48

203	Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. <i>Translational Lung Cancer Research</i> , 2015 , 4, 126-41	4.4	48
202	VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. <i>Journal of Pathology</i> , 2001 , 193, 325-32	9.4	47
201	Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. <i>Breast Cancer Research and Treatment</i> , 1996 , 38, 97-108	4.4	46
200	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. <i>Blood</i> , 2012 , 120, 822-32	2.2	45
199	Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. <i>British Journal of Cancer</i> , 2013 , 108, 1587-92	8.7	45
198	Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. <i>British Journal of Cancer</i> , 2015 , 112, 1411-20	8.7	44
197	Nuclear and cytoplasmic expressions of ER α and ER β are predictive of response to therapy and alters prognosis in familial breast cancers. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 395-405	4.4	44
196	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 385-92	4.4	43
195	"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 599-606	4.4	43
194	Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. <i>Annals of Oncology</i> , 1997 , 8, 271-5	10.3	43
193	Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 2008 , 111, 453-9	4.4	43
192	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. <i>Oncotarget</i> , 2018 , 9, 36126-36136	3.3	43
191	Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. <i>International Journal of Cancer</i> , 2014 , 135, 887-95	7.5	42
190	Relationship of the Breast Ductal Carcinoma Immune Microenvironment with Clinicopathological and Genetic Features. <i>Clinical Cancer Research</i> , 2017 , 23, 5210-5217	12.9	41
189	The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. <i>Oncotarget</i> , 2012 , 3, 893-906	3.3	41
188	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016 , 61, 111-21	7.5	41
187	HIF-1 β stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. <i>Breast Cancer Research</i> , 2013 , 15, R30	8.3	40
186	The epidermal growth factor receptor in breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1997 , 2, 131-41	2.4	40

185	Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. <i>Journal of Cell Science</i> , 2006 , 119, 910-22	5.3	40
184	A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. <i>Anticancer Research</i> , 2009 , 29, 1483-8	2.3	40
183	A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. <i>British Journal of Cancer</i> , 2014 , 111, 2254-61	8.7	39
182	Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. <i>Journal of Pathology</i> , 2005 , 205, 585-91	9.4	39
181	Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. <i>Scientific Reports</i> , 2017 , 7, 42259	4.9	38
180	Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 577-82	6.7	38
179	Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. <i>Prostate</i> , 2007 , 67, 1091-8	4.2	38
178	Apatinib for the treatment of gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 887-92	4.2	38
177	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. <i>Modern Pathology</i> , 2017 , 30, 952-963	9.8	37
176	RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. <i>British Journal of Cancer</i> , 2014 , 110, 1606-13	8.7	37
175	Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. <i>BMC Cancer</i> , 2012 , 12, 510	4.8	37
174	The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. <i>Breast Cancer Research</i> , 2011 , 13, R19	8.3	37
173	Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. <i>BMC Research Notes</i> , 2008 , 1, 14	2.3	35
172	The cancer genetics and pathology of male breast cancer. <i>Histopathology</i> , 2016 , 68, 110-8	7.3	35
171	Ductal carcinoma in situ - update on risk assessment and management. <i>Histopathology</i> , 2016 , 68, 96-109	7.3	34
170	Applicability of next generation sequencing technology in microsatellite instability testing. <i>Genes</i> , 2015 , 6, 46-59	4.2	34
169	Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. <i>Breast Cancer Research</i> , 2007 , 9, R89	8.3	34
168	Expression of cathepsin D and estrogen receptor in male breast carcinoma. <i>Human Pathology</i> , 1993 , 24, 148-51	3.7	34

167	Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCA1, but not BRCA1 familial breast cancers. <i>Breast Cancer Research</i> , 2012 , 14, R69	8.3	32
166	Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. <i>Oncology Reports</i> , 2011 , 25, 619-27	3.5	32
165	Synergistic activity of letrozole and sorafenib on breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 79-88	4.4	32
164	RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 105, 7-16	4.4	32
163	Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. <i>Journal of Pathology</i> , 2001 , 195, 236-43	9.4	32
162	Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. <i>Journal of Pathology</i> , 1992 , 166, 13-8	9.4	32
161	Cohesin Rad21 mediates loss of heterozygosity and is upregulated via Wnt promoting transcriptional dysregulation in gastrointestinal tumors. <i>Cell Reports</i> , 2014 , 9, 1781-1797	10.6	31
160	A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. <i>Scientific Reports</i> , 2013 , 3, 1659	4.9	31
159	DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 555-65	4.4	31
158	COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. <i>British Journal of Cancer</i> , 2014 , 111, 46-54	8.7	30
157	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016 , 68, 45-56	7.3	29
156	Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4120-4134	12.9	29
155	Targeting Mdmx to treat breast cancers with wild-type p53. <i>Cell Death and Disease</i> , 2015 , 6, e1821	9.8	28
154	Copy number analysis of ductal carcinoma in situ with and without recurrence. <i>Modern Pathology</i> , 2015 , 28, 1174-84	9.8	28
153	Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. <i>Oral Oncology</i> , 2013 , 49, 576-81	4.4	28
152	The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. <i>Prostate</i> , 2007 , 67, 623-9	4.2	28
151	Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue. <i>Genome Medicine</i> , 2016 , 8, 121	14.4	27
150	Triple negative breast cancers have a reduced expression of DNA repair genes. <i>PLoS ONE</i> , 2013 , 8, e66243	4.7	27

149	Langerhans cells in human lung tumours: an immunohistological study. <i>Histopathology</i> , 1989 , 14, 269-75	7.3	26
148	Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy. <i>Pathology</i> , 2017 , 49, 457-464	1.6	25
147	Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 617-24	4.4	25
146	A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. <i>BMC Cancer</i> , 2011 , 11, 265	4.8	25
145	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. <i>Cancer Research</i> , 2016 , 76, 4236-48	10.1	25
144	MDM4 is a rational target for treating breast cancers with mutant p53. <i>Journal of Pathology</i> , 2017 , 241, 661-670	9.4	24
143	Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. <i>British Journal of Cancer</i> , 2015 , 112, 52-60	8.7	23
142	Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. <i>Gene Therapy</i> , 2008 , 15, 1056-66	4	23
141	EGFR mutations in exons 18-21 in sporadic breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 203-205	10.3	23
140	Emerging entities in NUTM1-rearranged neoplasms. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 375-385	5	22
139	Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. <i>Oncogene</i> , 2016 , 35, 6235-6245	9.2	22
138	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. <i>Lung Cancer</i> , 2017 , 107, 22-35	5.9	21
137	CCL27/CCL28-CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells. <i>Cancer Research</i> , 2019 , 79, 1558-1572	10.1	21
136	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1 and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. <i>Breast Cancer Research</i> , 2011 , 13, R16	8.3	21
135	PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories. <i>Genome Medicine</i> , 2017 , 9, 38	14.4	20
134	Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer. <i>Science Signaling</i> , 2017 , 10,	8.8	19
133	Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. <i>Cell Cycle</i> , 2013 , 12, 1722-31	4.7	19
132	An Immunohistochemical and Prognostic Evaluation of Cathepsin D Expression in 105 Bladder Carcinomas. <i>Journal of Urology</i> , 1995 , 154, 237-241	2.5	19

131	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1940-1945	15.9	19
130	E6AP promotes prostate cancer by reducing p27 expression. <i>Oncotarget</i> , 2017 , 8, 42939-42948	3.3	19
129	PIK3CA mutations are frequently observed in BRCA1 but not BRCA2-associated male breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R69	8.3	18
128	A fully human inhibitory monoclonal antibody to the Wnt receptor RYK. <i>PLoS ONE</i> , 2013 , 8, e75447	3.7	18
127	VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. <i>Journal of Pathology</i> , 2016 , 239, 152-61	9.4	18
126	Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. <i>Science Signaling</i> , 2017 , 10,	8.8	17
125	Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. <i>Familial Cancer</i> , 2015 , 14, 287-95	3	17
124	Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. <i>Modern Pathology</i> , 2014 , 27, 1223-30	9.8	17
123	Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. <i>Annals of Oncology</i> , 2014 , 25, 2392-2397	10.3	17
122	Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0128861	3.7	17
121	Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. <i>British Journal of Cancer</i> , 2014 , 111, 2351-60	8.7	17
120	Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines. <i>Histopathology</i> , 1990 , 17, 69-74	7.3	17
119	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020 , 33, 354-366	9.8	17
118	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1610-1622	6.1	16
117	Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1332-1338	9.7	16
116	DNA methylation in ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2013 , 15, 206	8.3	16
115	Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. <i>Breast Cancer Research</i> , 2014 , 16, 423	8.3	16
114	Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. <i>Prostate</i> , 2008 , 68, 336-43	4.2	16

113	Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. <i>Journal of Clinical Pathology</i> , 2015 , 68, 362-7	3.9	15
112	The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. <i>Clinical Cancer Research</i> , 2013 , 19, 5740-8	12.9	15
111	CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. <i>EBioMedicine</i> , 2020 , 61, 103030	8.8	15
110	SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. <i>Npj Precision Oncology</i> , 2018 , 2, 9	9.8	14
109	Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 319-29	4.4	14
108	DNA methylation analysis of the HIF-1 α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. <i>Histopathology</i> , 2010 , 57, 451-60	7.3	14
107	A multiplex endpoint RT-PCR assay for quality assessment of RNA extracted from formalin-fixed paraffin-embedded tissues. <i>BMC Biotechnology</i> , 2010 , 10, 89	3.5	14
106	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. <i>Npj Breast Cancer</i> , 2020 , 6, 9	7.8	13
105	Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. <i>Histopathology</i> , 2016 , 68, 367-77	7.3	13
104	Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 113-21	4.4	13
103	Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples. <i>Oncotarget</i> , 2018 , 9, 6841-6851	3.3	13
102	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018 , 72, 1075-1083	7.3	13
101	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. <i>Journal of Pathology</i> , 2019 , 248, 326-338	9.4	12
100	Multimiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. <i>Pharmacogenomics</i> , 2013 , 14, 1405-17	2.6	12
99	Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 550-8	12.9	12
98	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020 , 107, 837-848	11	12
97	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2020 , 22, 91	8.3	12
96	CN spectator: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. <i>Scientific Reports</i> , 2019 , 9, 6426	4.9	11

95	Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. <i>BMC Cancer</i> , 2015 , 15, 506	4.8	11
94	Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. <i>BMC Cancer</i> , 2015 , 15, 669	4.8	11
93	No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. <i>BMC Research Notes</i> , 2009 , 2, 194	2.3	11
92	kConFab: a familial breast cancer consortium facilitating research and translational oncology. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 79-81	4.8	11
91	Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 795-804	4.4	11
90	Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. <i>International Journal of Cancer</i> , 2010 , 126, 1445-53	7.5	11
89	Second malignant tumors detected by needle aspiration cytology. <i>Cancer</i> , 1983 , 52, 699-706	6.4	11
88	LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. <i>Oncotarget</i> , 2017 , 8, 83626-83636	3.3	11
87	Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. <i>Diagnostic Molecular Pathology</i> , 2010 , 19, 187-93		10
86	More about: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 161-2	9.7	10
85	Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 1798-9; author reply 1801-2	9.7	10
84	Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms. <i>Medical Decision Making</i> , 2018 , 38, 954-967	2.5	10
83	GATA3 expression in triple-negative breast cancers. <i>Histopathology</i> , 2017 , 71, 63-71	7.3	9
82	National Working Group Meeting on ALK diagnostics in lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10 Suppl 2, 11-7	1.9	9
81	Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. <i>Breast Cancer Research</i> , 2011 , 13, R14	8.3	9
80	Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. <i>International Journal of Cancer</i> , 2011 , 128, 2735-47	7.5	9
79	Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosis. <i>Journal of Urology</i> , 2011 , 185, 1513-8	2.5	9
78	Molecular comparison of interval and screen-detected breast cancers. <i>Journal of Pathology</i> , 2019 , 248, 243-252	9.4	8

77	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. <i>Internal Medicine Journal</i> , 2018 , 48, 37-44	1.6	8
76	Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. <i>Oncolmmunology</i> , 2016 , 5, e1149667	7.2	8
75	Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis. <i>Breast Cancer Research</i> , 2016 , 18, 106	8.3	8
74	Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 665-78	6.4	8
73	HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. <i>Pathology</i> , 2017 , 49, 575-581	1.6	8
72	"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. <i>Journal of Personalized Medicine</i> , 2015 , 5, 354-69	3.6	8
71	HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?. <i>Pathology</i> , 2014 , 46, 184-7	1.6	8
70	A prospective pathologic study to define the clinical target volume for partial breast radiation therapy in women with early breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 1116-22	4	8
69	Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2012 , 48, 698-702	4.4	8
68	Assessing tumor angiogenesis in histological samples. <i>Methods in Molecular Biology</i> , 2009 , 467, 55-78	1.4	8
67	SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1108-1117	6.7	7
66	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. <i>Journal of Pathology</i> , 2017 , 242, 273-283	9.4	6
65	The fibrinolysis inhibitor E2 antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. <i>Growth Factors</i> , 2017 , 35, 61-75	1.6	6
64	High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer. <i>BJU International</i> , 2012 , 110, E1181-6	5.6	6
63	Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 99-102	4.8	6
62	Quantitative angiogenesis in breast cancer. <i>Methods in Molecular Medicine</i> , 2006 , 120, 161-87		6
61	Microscopic assessment of angiogenesis in tumors. <i>Methods in Molecular Medicine</i> , 2001 , 46, 29-46		6
60	Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. <i>Pathology</i> , 2016 , 48, 535-42	1.6	6

59	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. <i>IScience</i> , 2019 , 22, 1-15	6.1	6
58	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021 , 34, 194-206	9.8	6
57	Clinical cancer genomic analysis: data engineering required. <i>Lancet Oncology, The</i> , 2015 , 16, 1015-1017	21.7	5
56	HER2-positive breast cancer metastatic to intracranial meningioma: a case report. <i>Journal of Clinical Pathology</i> , 2013 , 66, 633-4	3.9	5
55	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2015 , 17, 80	8.3	5
54	Positron emission tomography and neoadjuvant therapy of breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 111-5	4.8	5
53	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1 α and Relation to Clinical Response. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 64-6	4.8	4
52	RAF1 rearrangements are common in pancreatic acinar cell carcinomas. <i>Modern Pathology</i> , 2020 , 33, 1811-1821	9.8	4
51	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020 , 25, 641-649	5.7	4
50	Improved next-generation sequencing pre-capture library yields and sequencing parameters using on-bead PCR. <i>BioTechniques</i> , 2020 , 68, 48-51	2.5	4
49	BRCA2 carriers with male breast cancer show elevated tumour methylation. <i>BMC Cancer</i> , 2017 , 17, 641	4.8	4
48	KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10, 261-5	1.9	4
47	Altered significance of DAmico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort. <i>BJU International</i> , 2015 , 116, 207-12	5.6	4
46	Controversies in the management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10, 216-27	1.9	4
45	Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 67-70	4.8	4
44	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. <i>Oncotarget</i> , 2017 , 8, 78870-78881	3.3	4
43	Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 7967-78	1.4	4
42	Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. <i>BMC Urology</i> , 2020 , 20, 171	2.2	4

41	A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. <i>Laboratory Investigation</i> , 2021 , 101, 26-37	5.9	4
40	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018 , 48, 786-794	1.6	3
39	Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. <i>Breast</i> , 2016 , 29, 55-61	3.6	3
38	Consensus approaches to best practice management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 188-198	1.9	3
37	Assessing Tumor Angiogenesis in Histological Samples. <i>Methods in Molecular Biology</i> , 2016 , 1430, 3-33	1.4	3
36	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021 , 78, 759-771	7.3	3
35	Canary: an atomic pipeline for clinical amplicon assays. <i>BMC Bioinformatics</i> , 2017 , 18, 555	3.6	2
34	Does cyclin D1 discriminate between BRCA2 and BRCA1 breast cancers?. <i>Histopathology</i> , 2009 , 55, 625-673	6.3	2
33	The molecular characterisation of unusual subcutaneous spindle cell lesion of breast. <i>Journal of Clinical Pathology</i> , 2012 , 65, 746-50	3.9	2
32	No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 853-6	4.4	2
31	Recurrent fusions in pediatric sarcoma and brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020 , 6,	2.8	2
30	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021 , 23, 1726-1737	8.1	2
29	Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. <i>JAMA Dermatology</i> , 2021 , 157, 836-841	5.1	2
28	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. <i>Modern Pathology</i> , 2021 , 34, 2130-2140	9.8	2
27	Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. <i>Cancer Research</i> , 2019 , 79, 3008	10.1	1
26	Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. <i>Drug Discovery Today</i> , 2015 , 20, 1429-32	8.8	1
25	Molecular profiling in colorectal cancer: current state of play and future directions. <i>Colorectal Cancer</i> , 2014 , 3, 41-56	0.8	1
24	Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missense mutations. <i>Pathology</i> , 2013 , 45, 604-6	1.6	1

23	Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?. <i>Oncoscience</i> , 2015 , 2, 567-9	0.8	1
22	Biobanking in Cancer Research 2016 , 27-49		1
21	Diagnostic and Prognostic Significance of Tumor Angiogenesis 2002 , 151-176		1
20	Using Genomic Sequencing to Explain an Exceptional Response to Therapy in a Malignant Phyllodes Tumor.. <i>JCO Precision Oncology</i> , 2020 , 4, 1263-1266	3.6	1
19	The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. <i>Npj Breast Cancer</i> , 2020 , 6, 34	7.8	1
18	EGFR mutation profile in Australian patients with non-small cell lung cancer. <i>Pathology</i> , 2021 , 53, 933-936	6.6	1
17	Reply to the Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast. <i>Histopathology</i> , 2016 , 69, 523-4	7.3	1
16	Precision oncology using a clinician-directed, tailored approach to molecular profiling. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 84-90	1.9	1
15	Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e185-e186	8.9	1
14	Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.. <i>JCO Precision Oncology</i> , 2021 , 5, 1160-1165	3.6	1
13	Male breast cancer: an update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	1
12	Angiogenesis in Mammary Tumors: Quantitation and Relation to Prognosis 2001 , 63-84		1
11	In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.. <i>EMBO Molecular Medicine</i> , 2021 , e14608	12	1
10	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. <i>Frontiers in Oncology</i> , 2021 , 11, 772052	5.3	0
9	MEK Inhibitor Therapy in Carcinomas With Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell Carcinoma.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-2	3.6	0
8	Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics.. <i>BMC Medical Genomics</i> , 2022 , 15, 70	3.7	0
7	In Response. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e85	8.9	
6	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 1-3	4.8	

- 5 Diagnostic issues with significant tumour displacement in breast biopsies. *Journal of Clinical Pathology*, **2014**, 67, 1110-1 3.9
- 4 BRCA1 associated breast cancers are frequently positive for ER and its cytoplasmic expression confers a poor prognosis. *Pathology*, **2009**, 41, 51 1.6
- 3 Steroid Hormone and Oncoprotein Expression in Male Breast Carcinoma. *Journal of Histotechnology*, **1991**, 14, 286-286 1.3
- 2 KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. *Colorectal Cancer*, **2016**, 5, 73-80 0.8
- 1 TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.. *Journal of Clinical Oncology*, **2022**, JCO2102108 2.2